Covered recipient · General Payments record
HOMA J PORTER
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$2,382.91
65 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,838.02 | 62 |
| Travel and Lodging | $544.89 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Olympus Corporation of the Americas | $544.89 | 3 |
| Sumitomo Pharma America, Inc. | $354.71 | 9 |
| Janssen Biotech, Inc. | $251.10 | 6 |
| Procept Biorobotics Corporation | $158.77 | 4 |
| IMMUNITYBIO, INC. | $128.35 | 5 |
| PFIZER INC. | $123.20 | 5 |
| Dendreon Pharmaceuticals LLC | $116.73 | 4 |
| Merck Sharp & Dohme LLC | $95.19 | 3 |
| Bayer Healthcare Pharmaceuticals Inc. | $89.82 | 4 |
| Olympus America Inc. | $76.87 | 3 |
| Astellas Pharma US Inc | $64.63 | 3 |
| Novartis Pharmaceuticals Corporation | $63.16 | 2 |
| Ferring Pharmaceuticals Inc. | $51.68 | 2 |
| ABBVIE INC. | $45.42 | 2 |
| Valencia Technologies Corporation | $45.27 | 2 |
| Azurity Pharmaceuticals, Inc. | $42.57 | 2 |
| Medtronic, Inc. | $37.26 | 1 |
| TOLMAR, INC. | $34.49 | 2 |
| Endo USA, Inc. | $20.41 | 1 |
| Boston Scientific Corporation | $19.66 | 1 |
| Verity Pharmaceuticals Inc. | $18.73 | 1 |
Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HOMA J PORTER
NPI 1073560058 · CMS profile ID 3114
Allopathic & Osteopathic Physicians / Urology
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1073560058?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HOMA J PORTER, NPI 1073560058, CMS profile ID 3114. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073560058?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). HOMA J PORTER, NPI 1073560058, CMS profile ID 3114. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073560058?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- HOMA J PORTER, NPI 1073560058, CMS profile ID 3114, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1073560058?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
65 matching records · $2,382.91 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 65.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $22.16 | 12/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225712499 | CMS |
| Novartis Pharmaceuticals Corporation | $29.27 | 12/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200660815 | CMS |
| PFIZER INC. | $28.11 | 12/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229773086 | CMS |
| Ferring Pharmaceuticals Inc. | $26.06 | 12/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242080734 | CMS |
| Sumitomo Pharma America, Inc. | $134.70 | 11/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176706557 | CMS |
| Dendreon Pharmaceuticals LLC | $31.18 | 11/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245008488 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $22.16 | 11/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225712496 | CMS |
| Olympus America Inc. | $45.66 | 11/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223087004 | CMS |
| ABBVIE INC. | $24.90 | 10/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203661293 | CMS |
| Janssen Biotech, Inc. | $22.96 | 10/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174997998 | CMS |
| PFIZER INC. | $23.77 | 10/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229368144 | CMS |
| Sumitomo Pharma America, Inc. | $19.12 | 10/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176706555 | CMS |
| Merck Sharp & Dohme LLC | $30.37 | 10/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238312842 | CMS |
| IMMUNITYBIO, INC. | $26.07 | 10/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233178757 | CMS |
| Valencia Technologies Corporation | $20.95 | 10/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218180946 | CMS |
| Sumitomo Pharma America, Inc. | $28.31 | 10/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176706553 | CMS |
| PFIZER INC. | $24.84 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229204342 | CMS |
| Janssen Biotech, Inc. | $23.81 | 09/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174997097 | CMS |
| IMMUNITYBIO, INC. | $33.43 | 09/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233177885 | CMS |
| Sumitomo Pharma America, Inc. | $29.79 | 08/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176706551 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $21.73 | 08/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225712493 | CMS |
| Astellas Pharma US Inc | $30.12 | 08/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238657984 | CMS |
| Procept Biorobotics Corporation | $24.57 | 08/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249753034 | CMS |
| Endo USA, Inc. | $20.41 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201214167 | CMS |
| Sumitomo Pharma America, Inc. | $28.32 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176706549 | CMS |
| Dendreon Pharmaceuticals LLC | $25.54 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245008486 | CMS |
| PFIZER INC. | $22.83 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231697089 | CMS |
| Janssen Biotech, Inc. | $21.73 | 07/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174992866 | CMS |
| Valencia Technologies Corporation | $24.32 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218180944 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $23.77 | 06/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225712491 | CMS |
| Verity Pharmaceuticals Inc. | $18.73 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234197848 | CMS |
| Procept Biorobotics Corporation | $43.55 | 06/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249753022 | CMS |
| Procept Biorobotics Corporation | $65.98 | 06/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249753024 | CMS |
| Dendreon Pharmaceuticals LLC | $26.40 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245008484 | CMS |
| Sumitomo Pharma America, Inc. | $27.96 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176706547 | CMS |
| Azurity Pharmaceuticals, Inc. | $21.02 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242677624 | CMS |
| Procept Biorobotics Corporation | $24.67 | 05/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249752922 | CMS |
| PFIZER INC. | $23.65 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231322599 | CMS |
| IMMUNITYBIO, INC. | $29.26 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233174988 | CMS |
| Merck Sharp & Dohme LLC | $31.73 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238043497 | CMS |
| Azurity Pharmaceuticals, Inc. | $21.55 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242677622 | CMS |
| TOLMAR, INC. | $19.29 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237010795 | CMS |
| Janssen Biotech, Inc. | $143.61 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174997609 | CMS |
| Janssen Biotech, Inc. | $15.07 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174998460 | CMS |
| Sumitomo Pharma America, Inc. | $29.10 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176706545 | CMS |
| Astellas Pharma US Inc | $19.03 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238775202 | CMS |
| TOLMAR, INC. | $15.20 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237010771 | CMS |
| Novartis Pharmaceuticals Corporation | $33.89 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200730308 | CMS |
| IMMUNITYBIO, INC. | $20.96 | 03/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233173532 | CMS |
| Ferring Pharmaceuticals Inc. | $25.62 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242080732 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $503,343.98 | 37 |
| PY2024 | Principal investigator | $739,851.51 | 38 |
| PY2023 | Principal investigator | $476,035.66 | 7 |
| PY2020 | Principal investigator | $20,519.40 | 6 |
| PY2019 | Recipient | $735.51 | 6 |
| PY2019 | Principal investigator | $58,065.60 | 10 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
37 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,491.28 | 12/31/2025 | Non-covered Recipient Entity Urology Clinics of North Texas, PLLC | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926385 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,218.00 | 12/29/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175409040 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,802.00 | 12/29/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175409093 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,008.00 | 12/29/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175409153 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,024.00 | 12/15/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175409163 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $18,598.70 | 12/01/2025 | Non-covered Recipient Entity Urology Clinics of North Texas, PLLC | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926383 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,538.00 | 11/25/2025 | Non-covered Recipient Entity Urology Clinics Of North Texas | An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies | No dispute reported | 06/30/2026 | 1225415244 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,232.00 | 11/07/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175409058 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,176.00 | 11/03/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175409063 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,104.00 | 10/23/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175409121 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,269.00 | 10/13/2025 | Non-covered Recipient Entity Urology Clinics Of North Texas | An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies | No dispute reported | 06/30/2026 | 1225414094 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,429.00 | 10/03/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175409109 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,423.00 | 10/02/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175409136 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,954.00 | 09/08/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175409088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,208.00 | 09/08/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175409158 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,736.00 | 08/11/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175409105 |
| Principal investigator 1 | Astellas Pharma Global Development | $464.00 | 07/31/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234187935 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,269.00 | 07/28/2025 | Non-covered Recipient Entity Urology Clinics Of North Texas | An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies | No dispute reported | 06/30/2026 | 1225412916 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,590.00 | 07/28/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175409046 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,639.00 | 07/07/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175409051 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,808.00 | 06/06/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175409077 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,538.00 | 06/02/2025 | Non-covered Recipient Entity Urology Clinics Of North Texas | An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies | No dispute reported | 06/30/2026 | 1225412374 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,141.00 | 06/02/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m | No dispute reported | 06/30/2026 | 1175409141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,035.00 | 05/19/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175409083 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,066.00 | 05/12/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175409032 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,900.00 | 04/30/2025 | Non-covered Recipient Entity Urology Clinics Of North Texas | BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies | No dispute reported | 06/30/2026 | 1225402589 |
| Principal investigator 1 | Astellas Pharma Global Development | $729.00 | 04/15/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234187933 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,750.00 | 04/07/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175409071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,879.00 | 04/07/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175409173 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,552.00 | 03/27/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175409132 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,193.00 | 03/19/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234187931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $72,792.00 | 03/10/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175409099 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,027.00 | 03/10/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175409126 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,269.00 | 02/25/2025 | Non-covered Recipient Entity Urology Clinics Of North Texas | BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies | No dispute reported | 06/30/2026 | 1225402647 |
| Principal investigator 1 | Janssen Research & Development, LLC | $41,822.00 | 02/03/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175409115 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,269.00 | 01/27/2025 | Non-covered Recipient Entity Urology Clinics Of North Texas | BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies | No dispute reported | 06/30/2026 | 1225403161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,401.00 | 01/02/2025 | Non-covered Recipient Entity UROLOGY CLINICS OF NORTH TEXAS PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175409147 |